Last reviewed · How we verify
NCT06033001
Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
trial testing [Lu-177]-PNT2002 in Castration-Resistant Prostatic Cancer. Temporarily not available.
Quick facts
| Lead sponsor | Lantheus Medical Imaging |
|---|---|
| Status | TEMPORARILY NOT AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 7 locations across United States |
Drugs / interventions tested
- [Lu-177]-PNT2002 — full drug profile →
Conditions studied
- Castration-Resistant Prostatic Cancer — all drugs for Castration-Resistant Prostatic Cancer →
Sponsor
Lantheus Medical Imaging — full company profile →
Who can join
18 and older, male only, with Castration-Resistant Prostatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this program is to provide access to \[Lu-177\]-PNT2002 to patients who have been diagnosed with prostate-specific membrane antigen (PMSA)-positive castration-resistant prostate cancer (mCRPC). Patients must have received at least 1 prior androgen pathway inhibitor (ARPI) and cannot be treated by currently available drugs or clinical trials. In this program participants will be administered \[Lu-177\]-PNT2002 intravenously every 8 weeks (about every 2 months) for 4 cycles, or 8 months of total treatment. During treatment, participants will be monitored with routine laboratory tests such as: * Hematology blood tests * Clinical Chemistry blood tests * Testosterone/Prostate Antigen levels blood test * Vital signs * Imaging * ECG
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06033001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Castration-Resistant Prostatic Cancer
Currently open trials in the same condition.
- NCT06863272 — A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Re · Phase 1, PHASE2 · recruiting
- NCT04104607 — The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma · Phase 1 · recruiting
- NCT03748641 — A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone fo · Phase 3 · active not recruiting
Other Lantheus Medical Imaging trials
Trials by the same sponsor.
- NCT03719612 — DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY · Phase 3 · completed
- NCT03571672 — DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06033001 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lantheus Medical Imaging
- Last refreshed: 13 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06033001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing